1. Are there differences in LDL-C target value attainment in Austrian federal states? Yes!
- Author
-
Pichler M, Lautsch D, Adler C, Bögl K, Drexel H, Eber B, Fauer C, Föchterle J, Föger B, Gansch K, Grafinger P, Lechleitner M, Ludvik B, Maurer G, Mörz R, Paulweber B, Pfeiffer KP, Prager R, Stark G, Toplak H, Traindl O, and Weitgasser R
- Subjects
- Aged, Austria, Cross-Sectional Studies, Drug Resistance, Ezetimibe, Female, Humans, Hypercholesterolemia epidemiology, Longitudinal Studies, Male, Middle Aged, Retreatment, Topography, Medical, Anticholesteremic Agents therapeutic use, Azetidines therapeutic use, Cholesterol, LDL blood, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia blood, Hypercholesterolemia drug therapy
- Abstract
Unlabelled: Low density lipoprotein (LDL-C) levels determine the cardiovascular risk. Previous studies indicated an LDL-C target attainment of around 50%, but no Austrian wide analysis on results for the federal states was available. We therefore sought to detect potential differences., Design: Open-label, non-interventional, longitudinal study, registered: www.clinicaltrials.gov NCT 01381679. In all, 746 statin treated patients not at LDL-C goal received intensified therapy for 12 months. The sample was split into nine subgroups, representing the federal states of Austria.We detected an east-west gradient for baseline LDL-C. Individual target values were achieved by 37.2% (range: 26.1-57.7%). After 12 months, LDL-C < 70 mg/l was achieved by 13.5% (5.9-38.5%). Univariate ANCOVA retrieved significant differences within the states (Upper Austria and Salzburg, p = 0.001 and p = 0.0015, respectively). Furthermore, the capacity of intensified lipid lowering therapy applied in practice was as high as -42% as compared to previous standard therapy (additional LDL-C reduction after switch from baseline therapy in Vorarlberg).
- Published
- 2013
- Full Text
- View/download PDF